Jim Cramer Says Avoid This Stock: ‘Too Expensive’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Blackline, Inc. (NASDAQ: BL) was an enterprise software company that was losing money.
Congressman Sells Stocks At End Of 2022 And Retires From Office: Taking Profits Or Warning Sign?
A member of Congress sold out of his positions of several stocks at the end of 2022. The move came as he finished his term serving the state of Texas and announced his retirement.
10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn’t No. 1)
A new report was out about the performance of members of the U.S. Congress who bought and sold stocks and options in 2022.
The report broke down unusual trading activity from members of Congress and also showed the members who beat the returns of the S&P 500.
Here are the highlights of the report.
Traders May Be Circulating A Report From Jan 2, 2023, Titled ‘Medicare May Not Cover 2 Alzheimer’s Drugs Poised For Approval’ – Politico
https://subscriber.politicopro.com/article/2023/01/medicare-may-not-cover-two-alzheimers-drugs-poised-for-approval-00075332
CMS currently requires patients be enrolled in a randomized trial to pay for a certain class of
Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $400
Barclays analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $395 to $400.
Here’s How Much $100 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 12.11% on an annualized basis…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration
Eli Lilly And Co (NYSE:LLY) and ProQR Therapeutics N.V. (NASDAQ:PRQR) have expanded their licensing and collaboration agreement focused on discovering, developing,…
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…